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IntroDuctIon
For decades, scientists have endeavored to develop methods 
for propagating and studying primary tumors and normal cells 
outside of the human body1,2. To date, traditional established 
cell lines have been the mainstay of cell, molecular and cancer 
biology. However, the establishment of tumor cell lines is hindered 
by the low rate of success (1–10%, depending on the tissue of 
origin and state of disease progression)3,52. More importantly, the 
complex heterogeneity of primary tumors is often lacking in these 
cell lines, and normal cell lines from many tissues do not exist, 
thereby preventing the use of such cultures for predicting tumor 
cell responses4. Tumor heterogeneity is recognizable at both the 
microscopic level (immunohistochemistry) and at the genetic level 
(DNA mutations and/or changes in RNA expression). Genetic 
analysis of primary tumor samples has further identified critical 
variations within the tumor groups and even the relatedness of 
tumors from different tissues5. Thus, genetic analysis is the core 
principle of predictive tumor biology and response to therapies. 
However, despite the great potential for using genomic analysis as 
the basis for patient care, it is clear that the interplay of genetics, 
epigenetics, signaling alterations and cell–cell interactions is 
probably best evaluated by in vitro and/or rapid ex vivo models. 
In this article, we present a protocol on how to establish primary 
epithelial cell cultures in vitro from healthy human tissue and 
human cancer samples. We compare the utility of the CR method 
with other models, including patient-derived xenografts (PDXs) 
and organoid cultures, for advancing diagnostic and regenerative 
medicine. In addition, we discuss the exciting potential for the 
CR method to be used as a complementary platform for basic, 
translational and clinical research.
Development and applications of the protocol
Unlike other model systems, this protocol has been proven to 
easily establish patient-derived CR cell cultures from both nor-
mal and cancer tissues that have the capacity to grow indefinitely 
without genetic manipulation6–8. The technique uses irradiated 
mouse fibroblast cells and the Rho-associated kinase (ROCK) 
inhibitor (Y-27632) to propagate epithelial cells. Originally, 
Y-27632 was identified in a caspase/kinase inhibitor library as
being capable of increasing the cloning efficiency of human
embryonic stem (ES) cells9 and, in later studies, as being capable
of increasing the viability of human keratinocyte stem cells10. 
When added to keratinocyte/feeder cocultures developed
by Green11, Y-27632 induced indefinite cell proliferation6. 
Unexpectedly, we observed that feeders and Y-27632 could be
used to establish both normal and tumor cell cultures from non-
keratinocyte tissues7. We also noted that the ability of feeders
and Y-27632 to induce unlimited cell proliferation is similar to
the ability of the HPV-16 E6 and E7 oncogenes to immortalize
cells. Both E6 and feeder cells activate telomerase7, whereas both
E7 and Y-27632 disrupt the actin cytoskeleton12 and inactivate
Rho13. The effects of Y-27632 are completely reversible8, in that
CR cultures stop proliferating or terminally differentiate after its
removal, depending on culture conditions.
The induction of CR is rapid (within 2 d) and results from repro-
gramming of the cell population rather than clonal selection8, 
as is the case with conventional cell lines. Unlike ES cells and 
induced pluripotent stem (iPS) cells , CR cells from normal tissue 
do not express high levels of Sox2, Oct4, Nanog or Klf4 (ref. 8) 
and do not form teratomas in mice7. Moreover, CR cells maintain 
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Historically, it has been difficult to propagate cells in vitro that are derived directly from human tumors or healthy tissue.  
However, in vitro preclinical models are essential tools for both the study of basic cancer biology and the promotion of 
translational research, including drug discovery and drug target identification. this protocol describes conditional reprogramming 
(cr), which involves coculture of irradiated mouse fibroblast feeder cells with normal and tumor human epithelial cells in the 
presence of a rho kinase inhibitor (Y-27632). cr cells can be used for various applications, including regenerative medicine, 
drug sensitivity testing, gene expression profiling and xenograft studies. the method requires a pathologist to differentiate 
healthy tissue from tumor tissue, and basic tissue culture skills. the protocol can be used with cells derived from both fresh and 
cryopreserved tissue samples. as approximately 1 million cells can be generated in 7 d, the technique is directly applicable  
to diagnostic and predictive medicine. Moreover, the epithelial cells can be propagated indefinitely in vitro, yet retain the  
capacity to become fully differentiated when placed into conditions that mimic their natural environment. 
developmental potential and do not require intricate manipu-
lation to differentiate into the tissue of origin6–8. In tumor CR  
cell cultures, phenotypic and genotypic features of the primary 
tumor are maintained7 and the technique has recently been  
used to identify an appropriate therapy for respiratory papil-
lomatosis14. Therefore, it is clear that potential applications of 
the CR method are far-reaching, and, as described by independ-
ent laboratories, it can be adapted for live biobanking7 and basic 
research15–21, as well as for diagnostic22,23, therapeutic21,24,25 and 
regenerative medicine21,26,27.
Overview of the procedure
Figure 1 shows an overview of the protocol beginning with a 
pathologist evaluating tissue biopsies grossly and microscopi-
cally. The biopsies are then bisected: one half is fixed in formalin, 
processed, paraffin-embedded and examined histologically. The 
pathologist evaluates the viability of the cells and the percentage  
of the biopsy sample that is composed of tumor cells. The other 
half of the specimen can be frozen at this stage, or dispersed 
into single cells by enzymatic digestion and plated in medium 
containing irradiated Swiss 3T3 J2 mouse fibroblasts (feeder  
cells) and Y-27632 (ROCK inhibitor). Epithelial cell colonies are 
readily visible after 2 d, and cultures usually reach confluence in 
~5 d. During this time, results of the histological analysis refine 
the initial determination of the tissue as normal, malignant or 
mixed. Subsequently, short tandem repeat (STR) profiling, com-
parative genomic hybridization and spectral karyotyping can be 
performed on both the original tissue and the corresponding CR 
cells to authenticate the derivation of the cultured cells.
Beyond supporting the rapid expansion of primary epithelial 
cells in vitro, the CR method conditionally induces long-term 
proliferation. For example, as shown in Figure 2a, primary pros-
tate and mammary cells were passaged every 3 d in CR coculture 
at 1:4–1:32 dilutions and continued to proliferate at the same 
rate for at least 110 d and 100 population doublings until the 
experiment was terminated. STR analysis of the prostate cells at 
passage 33 confirmed genetic stability of the CR cells as com-
pared with the initial population7. By contrast, only 20 popula-
tion doublings were supported by traditional cell culture media 
(Fig. 2a). The morphology of epithelial cell colonies growing 
in CR coculture with feeders at passage 4 (eight population 
doublings) is shown in Figure 2b.
Importantly, CR cells retain lineage commitment and differen-










































Figure 1 | Overview of the CR method for collection of specimens, establishment of cultures and potential applications of CR technology. Briefly, human tissue 
samples are obtained from surgical and core biopsies, fine-needle aspiration (FNA) or patient-derived xenograft (PDX) tissue. The samples are thoroughly 
evaluated by a pathologist using immunohistochemistry (IHC), and specific biomarkers are identified to ensure their normal/tumor status. CR cell lines are 
generated from the tissue samples using coculture with irradiated J2 feeder cells and ROCK inhibitor, and then are banked in liquid nitrogen. Subsequently, the 
authenticity of the cell lines should be validated by short tandem repeat (STR) profiling, comparative genomic hybridization (CGH) and spectral karyotyping 
(SKY). The CR cells can then be used for various applications, including regenerative medicine, drug sensitivity testing, gene expression profiling and xenograft 
studies. ‘Pathology evaluation’ image courtesy of V.R. Dowell (CDC; Public Health Image Library ID no. 14677). ‘Regenerative medicine’ image reproduced with 
permission from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Human tissue samples were collected with 
the informed consent of patients, according to Georgetown University Institutional Review Board protocols.
For example, Figure 3a shows that CR keratinocytes form fol-
licular and epidermal lineages when grafted as dermal–epidermal 
composites, as described earlier for non-CR keratinocytes28,29. 
In addition, a well-differentiated prostate epithelium that 
expresses the androgen receptor forms when CR prostate cells 
are injected below the renal capsule of an immunodeficient 
mouse30 (Fig. 3b). Finally, CR tracheal–bronchial cells differen-
tiate into both ciliated cells and mucocytes in vitro27,31 (Fig. 3c,d, 
Supplementary Video 1).
Comparison with other methods
The most common method of immortalizing cells has been 
transformation with SV40 virus large T antigen or overexpres-
sion of hTERT32,33. However, these genetic manipulations lead 
to genomic instability, such that after a few passages there is an 
irreversible loss of critical biological and genetic characteristics as 
compared with those of the primary tissues from which they were 
derived34. Most primary cell cultures, regardless of the method 
used to generate them, are difficult to maintain, as they have a 
limited life span because of a gradual decrease in proliferation, 
eventually leading to senescence34,35.
Both ES and iPS cells can be propagated in vitro and retain a 
normal karyotype. They can differentiate into several germ layers 
and show great potential in regenerative medicine36,37. However, 
with limited exceptions, it is not feasible to precisely direct their 
differentiation into specific adult tissues. In addition, the use 
of human ES cells can, in certain cases, be prohibited for ethi-
cal reasons38. Generation of iPS cells from adult tissues usually 







































Figure 2 | CR cells are conditionally immortalized. (a) Normal prostate and 
mammary epithelial cells were propagated in both CR culture and synthetic 
media (prostate epithelial cell growth medium and mammary epithelial cell 
growth medium). Growth curves were plotted using cumulative population 
doubling time over time. a adapted with permission from ref. 7, Elsevier. 
(b) Morphology of primary tracheal–bronchial cells (TBCs) growing in CR
coculture with irradiated J2 feeder cells (J2s) at passage 4 (eight population
doublings). Scale bar, 100 µm. Human tissue specimens were collected
with the informed consent of patients according to Georgetown University










Figure 3 | CR cells maintain lineage commitment in vitro and in vivo. 
(a) Dermal–epidermal composites were constructed using CR human neonatal
foreskin keratinocytes and human dermal papilla cells (both passage 3)
grafted to nude mice. H&E staining of sections of grafts obtained after
8 weeks show hair follicle structures and interfollicular stratified squamous
epithelium. The epithelial cells stain positively with a human-specific
antibody (COX IV), confirming their identity as human (anti-COX IV antibody
from Cell Signaling, cat. no. 4850, 1:500 dilution). Scale bars, 100 µm.
(b) Well-differentiated prostate epithelium formed from normal human
prostate CR cells co-injected into the renal capsule of an immunodeficient
mouse along with Matrigel and urogenital mesenchyme cells (these specifics
are essential)39. H&E staining shows normal prostate morphology and
prostatic secretions. The prostate epithelium expresses the androgen receptor
(AR; Santa Cruz Biotechnology antibody, cat. no. sc-816, 1:500 dilution).
Scale bars, 100 µm. (c) Tracheal–bronchial CR cells were differentiated in
air–liquid interface culture. Confocal microscopy demonstrates the presence
of cilia (white: α-tubulin; Millipore antibody, cat. no. MAB1854, 1:500
dilution), mucins (green: Muc 5AC/Muc 5B; Thermo/Lab Vision antibody,
cat. no. MS-551, 1 µg/ml), F-actin (red: AlexaFluor 488-phalloidin; Molecular
Probes, cat. no. A12379, 200 units/ml) and DNA (blue: Hoechst 33258,
Molecular Probes, cat. no. H3569, 1:1,000 dilution). Scale bar, 30 µm.
c adapted with permission from ref. 8, National Academy of Sciences.
(d) Low-magnification view of differentiated tracheal–bronchial CR cells
showing bronchosphere. Scale bar, 20 µm. Inset is a high-magnification
frame of the bronchosphere from time-lapse photography (supplementary
Video 1) showing cilia. Scale bar, 10 µm. Tissue specimens were collected
with the informed consent of patients, according to Georgetown University
and The University of North Carolina School of Medicine Institutional
Review Board protocols.
growth and differentiation properties37, unlike the generation of 
CR cells, which maintain lineage commitment. More recently,  
a defined chemical method has been used to generate iPS cells  
and, although promising, further testing and verification are 
required before this reprogramming method can be used in 
regenerative medicine39.
In recent years, PDXs have emerged as a system that in some 
respects serves as a better model for cancer studies than cultured 
cells40. They often preserve the molecular and cellular basis of 
tumor heterogeneity41 and have been shown in certain cases to 
predict therapeutic responses42. However, as PDX models are 
established from tumors as subcutaneous xenografts in mice, the 
normal tissue counterpart and surrounding interacting stroma of 
each patient is missing. Humanized PDX models are costly, difficult  
to develop and not amenable to high-throughput platforms; in 
addition, their success rates frequently fall below 30%42,43.
Clevers44–46, Guo47,48 and colleagues have successfully estab-
lished 3D organoid cultures of epithelial cells using Matrigel or 
collagen. The organoid culture method supports the growth of 
both normal and cancer tissue, and cultures can be manipulated 
at the genetic level by transfection49. Although organoids are  
also useful for evaluating drug responses, they are not readily 
adaptable to high-throughput screening.
Limitations of the CR method
A limitation of the basic CR method is that the outgrowth of 
human stromal cells in biopsies is inhibited. This phenomenon 
was observed decades ago and was attributed to the J2 feeder 
cells11. Thus, although overgrowth of tumor-associated fibroblasts 














supplementF medium J2 cells Y-27632
Breast (N, T) + + +
Prostate (N, T) + + +
Lung (N, T) + + +
Cervix (N, T) + + +
Oral (N, T) + + +
Ovary (N, T) + + +
Skin (N, T) + + +
Salivary gland (N,T) + + +
Kidney (N, T) + + +
Colon (T) + + + + +
Colon (N) + + + + +
Pancreas (N, T) + + + + +
Thyroid (N, T) + + + +
Schwannomas + + + + +
Neuroendocrine cells (T) + + +
GIST cells (T) + + +
Normal (N) and tumor (T) cells from various tissues, including pancreas, colon and neuroendocrine carcinoma (Fig. 4) require modifications of standard CR culture conditions for optimal proliferation.  




Figure 4 | Modification of standard CR conditions for certain tissue-derived 
cells. CR cell cultures from pancreas, colon and neuroendocrine cervical 
carcinoma exhibited unique morphologies and required modifications of 
standard CR culture conditions for optimal proliferation (table 1). The CR 
neuroendocrine cervical carcinoma cells form tumors in nude mice equivalent 
to the primary tumor (data not shown). The differentiation of pancreas and 
colon CR cells has not been evaluated. Scale bars, 200 µm (colon), 400 µm 
(pancreas and neuroendocrine cervical carcinoma). Tissue specimens were 
collected with the informed consent of patients according to Georgetown 
University Institutional Review Board protocols.
is inhibited, which allows selected propagation of epithelial 
carcinomas, it is difficult to assay the influence of stromal cells on 
tumor cell growth and their effect on the response of the tumor 
cells to therapeutic agents. However, previously unpublished 
modifications of the CR method have allowed some stromal 
tumors to be propagated, opening new possibilities for the exami-
nation of direct epithelial/stromal interactions (Table 1).
Another limitation of the method is that the use of the Y-27632 
might potentially interfere with migration and invasion assays 
of tumor cells, as it alters the actin cytoskeleton. Interestingly, 
however, we have been able to distinguish normal and tumor cells 
in invasion assays even in the presence of Y-27632, suggesting 
that this biological activity is not blocked under CR conditions 
(Supplementary Fig. 1).
Finally, the CR method allows the outgrowth of both normal 
and tumor epithelial cells, which means that cultures of biop-
sies will often contain such mixtures. Indeed, the replication of 
normal cells can sometimes exceed that of tumor cells, 
and thereby the normal cells eventually overtake the culture. 
However, previously unpublished, minor modifications of the 
standard CR method (such as eliminating the feeder cell com-
ponent) can select for certain tumor cells in a mixed population 
(Table 1, Fig. 4).
Experimental design
It is important to examine the biopsy material histologically, as in 
our experience ~25% of the tumor biopsies of primary prostate 
carcinomas from whole prostatectomy specimens contained no 
tumor cells. Similarly, 50% of the prostate carcinoma biopsies 
contained fewer than 10% tumor cells. Biopsies of normal regions 
of the prostate from the same patient usually contained mostly 
normal cells, but there were samples in which tumor cells were 
present (Fig. 5, Table 2).
Irradiated J2 feeder cells should be plated at a confluence of 
70–80% for optimal CR coculture (Fig. 6a). Feeder cells support 
epithelial cell growth, and colonies form rapidly as a consequence 
of proliferation and subsequent migration and merging of small 
colonies into larger colonies (Fig. 6b, Supplementary Video 2). By 
contrast, feeder cells inhibit the growth of fibroblast and stromal 
cells, as shown for gastrointestinal stromal tumor (GIST) cells in 
Figure 6c. It is clear from these results that GIST cells proliferate 
in CR medium only in the absence of feeders. Removal of feeder 
cells is also optimal for the growth of cells from the pancreas and 
colon (Fig. 4).
In addition to these changes, we found that it is possible to 
replace FBS with a defined serum replacement (knockout serum 
replacement; KSR) in all CR cocultures containing J2 cells (Fig. 6d). 
Furthermore, J2 cells can be replaced by medium conditioned 
by irradiated J2 cells (conditioned medium; CM) for established 
CR cultures (i.e., after three passages using standard coculture 
conditions), thereby eliminating the need to constantly maintain 
and irradiate J2 cells50. CM is critical for growing some cells in 
low O2 and makes high-throughput assays much simpler, as any 
background that could be attributed to feeder cells is eliminated. 
However, unless CM is specifically listed for a cell type in Table 1, 
standard coculture conditions should be used.
Acquired as tumor (1)
40% tumor
PP-004
Acquired as tumor (2)
0% tumor
Acquired as normal (1)
1% tumor
Acquired as normal (2)
60% tumor
Figure 5 | Evaluation of paired tumor and normal biopsies. Thirty-seven cases of primary prostate cancer were enrolled in the present study. A board-certified 
pathologist at Georgetown University Medical Center (B.K.) collected biopsies from four sites for each case: two that were deemed malignant and two that 
were deemed normal. For each biopsy, slices were made for CR culture and for histological evaluation. Using hematoxylin to stain proteins, filaments and 
intracellular membranes (pink) and eosin to stain nuclei and nucleic acids (blue), the percentages of tumor cells in the biopsies were determined according  
to standard histopathological criteria (table 2). Representative histological images are shown for patient PP-004. Scale bars, 100 µm; scale bars apply  




Amphotericin B, 250 µg/ml (Fisher Scientific, cat. no. BP264550)
B-27 Supplement (50×) (Gibco, cat. no. 17504044)
Cholera toxin, 11.7 µM (Sigma-Aldrich, cat. no. C-3012)  
! cautIon Cholera toxin is toxic. Handle it with gloves.
Collagen I, rat tail, 1 mg/ml (Corning, cat. no. 354236)
Collagenase IV, 1 mg/ml (Stemcell Technologies, cat. no. 07909)
Collagenase/hyaluronidase solution (10×; Fisher Scientific, 
cat. no. NC-9694308)
Deionized water
Dispase (Fischer Scientific, cat. no. 354235)










DMSO (Fisher Scientific, cat. no. BP-231-100)
Epidermal growth factor (EGF), human recombinant, 0.125 µg/ml  
(Life Technologies, cat. no. PHG0313)
Endothelial Cell Growth Medium (EGM-2, Lonza, cat. no. CC-3162)
Ethanol 200 proof, anhydrous (Fisher Scientific, cat. no. AC 61510-0010)
Ethanol, 70% (vol/vol) (Fisher Scientific, cat. no. R40135)
F-12 nutrient mix (Gibco, cat. no. 11765-054)
FBS (Gibco, cat. no.16140-071)
Gelatin, 0.1% solution (EMD Millipore, cat. no. ES-006-B or equivalent)
Gentamicin, 10 mg/ml (Gibco, cat. no. 15710-064)
Human patient tissue (We have used this protocol on prostate, breast,  











table 2 | Evaluation of paired tumor and normal patient prostate biopsies.
patient 
no.




tumor no. 2  
location slide results








PP-001 Left mid 5% tumor Left posterior 70% tumor Apex 0% tumor Mid 0% tumor
PP-002 Right apex 100% 
tumor
Left apex 20% tumor Right mid 
anterior
0% tumor Left mid 
anterior
5% tumor
PP-003 Right mid 1% tumor Right 
anterior mid
1% tumor Left mid 5% tumor Left mid 
anterior
0% tumor
PP-004 Left mid 40% tumor Left base 0% tumor Right mid/base 1% tumor Right base 60% tumor
PP-005 Left apex/mid 0% tumor Left mid/base 5% tumor Right mid 0% tumor Right mid 0% tumor
PP-006 Right base 60% tumor Right apex 90% tumor Left apex/mid 1% tumor Left mid 0% tumor
PP-007 Left apex 5% tumor NA NA Right apex 0% tumor Right mid 0% tumor
PP-008 Right mid 80% tumor ? NA Left mid 0% tumor ? NA
PP-009 Left base 0% tumor Left mid/base 60% tumor Right mid 0% tumor Right 
mid/apex
0% tumor
PP-010 Right 0% tumor NA NA Right 0% tumor Left 0% tumor
PP-011 Left base 
lateral
1% tumor Left base 5% tumor Right apex 1% tumor ? NA
PP-012 Left apex 80% tumor Right base 0% tumor Right mid 0% tumor Left mid 50% tumor
PP-013 Right apex 20% tumor Right mid 1% tumor Left mid 5% tumor Left apex 0% tumor
PP-014 Right base 0% tumor Right base 0% tumor Left mid 0% tumor Left mid 0% tumor
PP-015 Left apex 0% tumor Left mid 0% tumor Right apex 0% tumor Right mid 0% tumor
PP-016 Right 
base/mid
80% tumor Left mid 80% tumor Right mid/apex 100% tumor Right base 1% tumor
PP-017 Right mid 80% tumor Left mid/apex 0% tumor Right mid/base 0% tumor Left apex 0% tumor
PP-018 Left mid/apex 0% tumor Left mid 0% tumor Right mid 0% tumor Right base 0% tumor
PP-019 Right apex 
no. 1
1% tumor Right apex 
no. 2





5% tumor Left/right 
apex
90% tumor Right base 0% tumor Left base 0% tumor
PP-021 Left mid 
anterior
90% tumor Left mid 
posterior
30% tumor Right mid 100% tumor Right 
mid/base
0% tumor
PP-022 Right mid 20% tumor Right 
mid/base
10% tumor Left mid 0% tumor Left 
mid/base
0% tumor
PP-023 Left mid/base 0% tumor Left 
lateral mid
100% tumor Left mid 0% tumor Right 
apex/mid
0% tumor
PP-024 Left apex/mid 
no. 1
70% tumor Left apex/mid 
no. 2
10% tumor Right mid 0% tumor Right 
mid/base
0% tumor
PP-025 Left mid 90% tumor Right 
apex/mid
90% tumor Left mid 0% tumor Right 
apex/mid
30% tumor
PP-026 Right mid 80% tumor Left mid 70% tumor Right mid/base 0% tumor Left mid/base 0% tumor
PP-027 Left mid 
anterior
20% tumor Left base 5% tumor Right mid 5% tumor Right base 10% tumor
PP-028 Left base 80% tumor Left mid/base No slide Right mid/base 0% tumor Right mid 0% tumor
Twenty-eight out of thirty-seven cases of primary prostate cancer enrolled in the present study are shown; representative histological images are shown for patient PP-004 in Figure 5. Mid, middle;  
NA, not available.
! cautIon Normal or tumorous human specimens must be collected 
with the informed consent of the donors. Example data shown here were 
obtained according to Georgetown University Institutional Review Board 
protocols. ! cautIon Every unfixed human tissue should be treated as if it 
is known to be infectious for HIV, HBV or other blood-borne pathogens. 
Handle tissues with gloves. ! cautIon The cell lines generated should 
be regularly checked to ensure that they are authentic and are not 
infected with mycoplasma.
Human umbilical vein endothelial cells (HUVECs, Lonza cat. no. C2519AS)
Hydrocortisone, 25 µg/ml (Sigma-Aldrich, cat. no. H-0888)
Insulin, 5 mg/ml (Sigma-Aldrich, cat. no. I-5500)
Knockout serum replacement (Gibco, cat. no. 10828-028)
l-Glutamine, 200 mM (Gibco, cat. no. 25030-081)
Mammary epithelial cell growth medium (MEGM; Lonza, 
cat. no. CC-3051)
N-2 Supplement, 100× (Thermo Fisher Scientific, cat. no. 17502048)
Nystatin, 50 mg/ml (Sigma-Aldrich, cat. no. N6261)










Penicillin/streptomycin (pen/strep) mix, 10,000 U/ml (penicillin),  
10,000 µg/ml (streptomycin) (Gibco, cat. no. 15140-122)
Poly-l-ornithine solution, 0.01% (Sigma-Aldrich, cat. no. P4957)
Prostate epithelial cell growth medium (PrEGM; Lonza, cat. no. CC-3166)
ROCK inhibitor (Y-27632), 10 mM in sterile water (Enzo,  
cat. no. 270-333M025)
R-Spondin-1, human recombinant, 5 µg/ml (PeproTech, cat. no. 120-38)
Trypsin/EDTA 0.05% (Gibco, cat. no. 25300120)
Trypsin/EDTA 0.25% (Gibco, cat. no. 25200114)
EQUIPMENT
Aluminum foil (Fisher Scientific, cat. no. 01-213-100 or equivalent)
Biopsy processing/embedding cassettes (Simport, cat. no. M506-2)
Biopsy foam pads (Simport, cat. no. M476-1)
Cell culture flasks, CELLSTAR, 25 cm2, 75 cm2, 175 cm2 (Greiner Bio-One, 
cat. nos. 690160, 658170 and 660 or equivalent)
Cell culture incubator (37 °C, 95% humidity, 5% CO2; HERACELL 150i; 
cat. no. 51026282 or equivalent)
Cell culture variable oxygen control incubator (37 °C, 95% humidity, 5% 
CO2, 2% O2; HERACELL 150i, cat. no. 51026408 or equivalent)
Cell strainer, 100 µm (Corning, cat. no. 431752 or equivalent)
CryoTube vials, 1.8 ml (Thermo Scientific, cat. no. 375418 or equivalent)
Disposable sterile plastic pipettes, CELLSTAR, 5 ml, 10 ml, 25 ml  
(cat. nos. EK-33107, EK-34107, EK-53107, or equivalent)
Dissecting forceps (Fisher Scientific, cat. no. 08875 or equivalent)
E-plates 16 (ACEA Biosciences, cat. no. 05469830001)
EVOS XL digital inverted microscope (×4, ×10, ×20, ×40 objectives; 
Advanced Microscopy Group, cat. no. AMEX1000)
Examination gloves, powder-free, nitrile (VWR, cat. no. 82026 
or equivalent)
Freezer, −80 °C (Thermo Scientific, cat. no. TSX600D or equivalent)
Inverted phase-contrast microscope (×4, ×10, ×20 objectives; Zeiss 
Primovert, cat. no. 4155101100000000 or equivalent)
Laminar flow hood with vacuum (Thermo Electron Corporation, 
cat. no. 1323TS or equivalent)
Liquid nitrogen freezer (Kryos, K-series Cryostage Systems; 
Taylor-Wharton, cat. no. 6900-62 or equivalent)
Microcentrifuge, accuSpin Micro 17 (Fisher Scientific, cat. no. 13-100-675 
or equivalent)
Microcentrifuge tubes, Costar, 1.7 ml (Sigma-Aldrich, cat. no. CLS3620 
or equivalent)
P1000, P200, P20 Rainin automatic pipettes with sterile tips with filter 
(Rainin, cat. no. 17014406 or equivalent)
Pipet-Aid (Drummond, cat. no. 4-000-105)
Refrigerated centrifuge, Beckman Allegra 6R with CH-3.8 swinging bucket 
rotor (Beckman Coulter, cat. no. 366816 or equivalent)
Rocking double-tier platform (VWR, cat. no. 40000-304 or equivalent)
Scalpels, stainless steel surgical blade (Bard-Parker, cat. no. 08-915-18 
or equivalent)
Scepter handheld automated cell counter (Millipore, cat. no. PHCC20060), 
with disposable Scepter Sensors (cat. no. PHCC60050 or equivalent)
Sealing sterilization pouch (Fisher Scientific, cat. no. 01-812-54 
or equivalent)
Time-lapse microscope (Nikon Eclipse TE-300 Spinning Disk Timelapse 
Microscope System) with Volocity 6.2.1 computer software (PerkinElmer 
or equivalent)
Tissue culture plates, 6 wells, 12 wells and 96 wells (VWR, 
cat. nos. 10062-892, 10062-894, 10062-900 or equivalent)
Tubes, conical bottom, CELLSTAR, 15 ml and 50 ml (cat. nos. 82050-278, 
82050-350 or equivalent)
Vacuum filtration unit, 500 ml (VWR, cat. no. 10040-436 or equivalent)
Water bath, 37 °C (VWR, cat. no. 89501-460 or equivalent)
xCELLigence real-time cell analysis (RTCA) dual-purpose (DP) 
complete system (Acea Biosciences, cat. no. 00380601050)
REAGENT SETUP
Complete DMEM (1×) Mix 500 ml of DMEM, 50 ml of FBS, 5.5 ml 
of l-glutamine and 5.5 ml of pen/strep. Store the mixture at 4 °C for 
up to 4 months.
Hydrocortisone/EGF mix (1,000×) Dissolve hydrocortisone in 100% 
ethanol at a concentration of 0.5 mg/ml. Mix 1 ml with 19 ml of DMEM 
containing 2.5 µg of EGF. Store sterile 1.1-ml aliquots at −20 °C for up to 
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Figure 6 | Irradiated feeder cells, conditioned medium and serum 
replacement. (a) Irradiated J2 feeder cells plated at 70–80% confluence. 
Scale bar, 400 µm. (b) Colonies of primary epithelial cells (Epi) form  
between irradiated feeder cells (J2) by proliferation and rapid merging of 
small colonies (also see supplementary Video 2). Scale bars, 30 µm.  
(c) Proliferation of fibroblast/stromal cells is inhibited by irradiated
feeder cells. Gastrointestinal stromal tumor (GIST) cells proliferate
in F medium containing Y-27632 (FY) only when feeder cells (FYJ2) are
not present (compare left and right images). Scale bars, 400 µm.
The graph shows proliferation of GIST cells (measured as population
doublings) in FY in the presence (blue line) or absence (red line) of
irradiated J2 feeder cells. (d) Both FBS and knockout serum replacement
(KSR) similarly support the proliferation of primary human keratinocytes in
CR culture, or in culture with conditioned medium (CM FBS, CM KSR).
Scale bars, 200 µm. Human tissue specimens were collected with the
informed consent of patients, according to Georgetown University
Institutional Review Board protocols.
Complete F medium (1×) For 500 ml, mix 373 ml of complete DMEM, 125 ml  
of F12 nutrient mix, 0.5 ml of hydrocortisone/ EGF mix, 0.5 ml of insulin,  
0.5 ml of amphotericin B, 0.5 ml of gentamicin and 4.3 µl of cholera toxin. 
Filter-sterilize the solution using a 0.2-µm sterile filter and store it at 4 °C 
for up to 2 weeks (final concentrations: insulin, 5 µg/ml; amphotericin B, 250 
ng/ml; gentamicin, 10 µg/ml; cholera toxin, 0.1 nM; EGF, 0.125 ng/ml; hydro-
cortisone, 25 ng/ml). After adding the ROCK inhibitor Y-27632 at a final con-
centration of 10 µM, the medium may be stored at 4 °C for up to 2 months.
Sample collection (transport medium) Mix 500 ml of DMEM, 20 ml of 
pen/strep mix (100×), 2 ml of gentamicin (10 mg/ml), 1 ml of amphotericin 
B (250 µg/ml) and 1 ml of nystatin (50 mg/ml). Store the medium at 4 °C  
for up to 1 year. Add 10 µM Y-27632 immediately before use.
Cryopreservation medium Mix 90% FBS, 10% DMSO and 10 µM Y-27632. 
Store the medium at −80 °C for up to 6 months.
Collagen-coated flasks/wells Prepare 1 mg/ml collagen I solution using  
sterile deionized water, and store it at 4 °C overnight. Cover the bottom of 
a flask/dish with diluted collagen I (1 ml for a T25 flask; 0.5 ml per well of a 
six-well plate) and keep it at room temperature (18–22 °C) for 30 min. Trans-
fer the flask/dish to 4 °C for another 30 min. Aspirate leftover collagen I, rinse 
once with PBS and aspirate it. Store the flask/dish at room temperature  
for up to 4 weeks.
Poly-l-ornithine-coated flasks/wells Cover the bottom of a flask/dish  
with 0.01% poly-l-ornithine solution (2 ml for a T25 flask; 1 ml per  
well of a 6-well plate) and keep it at room temperature for 1 h. Aspirate  
the poly-l-ornithine solution and rinse the flask/dish once with sterile 
deionized water. Aspirate the water and repeat this step twice more. Let the 
flask/dish dry completely (lid on) in a cell culture hood. Store the flask/dish 
at 4 °C, wrapped in aluminum foil, for up to 4 weeks.
proceDure
Feeder cell culture ● tIMInG 1 h
1| Maintain Swiss-3T3-J2 mouse fibroblasts at 37 °C and 5% CO2 in complete DMEM and passage two to three times 
per week.
 crItIcal step Use only the J2 strain of Swiss-3T3 mouse fibroblasts as feeder cells for CR cocultures. The J2 cell line 
should be  regularly checked to ensure that it is not infected with mycoplasma.
? troublesHootInG
2| To passage J2 cells, rinse with PBS and incubate with 0.05% trypsin/EDTA solution at room temperature for 20 s.  
Monitor closely using a phase-contrast microscope. When the cells look round and begin to detach from the substrate, 
tap the cultures gently to detach the cells.
3| Stop the trypsin/EDTA incubation by adding four volumes of complete DMEM to the cells.
4| Centrifuge the cells at 300g for 5 min at 4 °C.
5| Resuspend the cell pellet in 10 ml of complete DMEM. Plate 1 × 103 cells/cm2 if the next passage will occur  
after 3 d. If you require the next passage to occur after 2 d, plate 2.3 × 103 cells/cm2, and if you are passaging after 1 d, 
plate 4 × 103 cells/cm2. Incubate the plate at 37 °C and 5% CO2 in complete DMEM.
Fresh tissue handling, transportation and shipping ● tIMInG 0.5 h
 crItIcal Only de-identified, coded, consented and institutional review board–approved specimens should be used in  
this protocol. Undertake the following steps in sterile conditions within 12 h after surgery.
6| Quickly rinse resected tissue sample(s) with 95–100% ethanol (up to 3 s) and then with cold (4 °C) PBS, and transfer 
to a sterile Petri dish. Using a set of forceps and a scalpel, remove residual fat tissue.
! cautIon Do not extend ethanol rinse time longer than 3 s.
7| Cut fresh specimen/s into small (<10 mm) pieces.
 crItIcal step Every unfixed human tissue should be handled with caution to prevent risk of infection from blood-borne 
pathogens. Wear a protective coat and handle human tissue specimens with gloves.
8| Dissect the tumor lesions from surrounding normal tissues as thoroughly as possible. Use at least one section from each 
sample for pathology.
9| If you are handling paired normal and tumor samples from the same subject, place each sample in a separate, clearly 
labeled container. The matching normal tissue should be taken from a site that is as far from the tumor lesion as possible.
10| Place all specimens (in separate containers) with 4 ml of sample collection (transport) medium. Close the lids of the 
containers tightly.
11| Package the samples with wet ice bags (4 °C) and ship using priority overnight delivery.
 crItIcal step Never snap-freeze or fix the samples before shipping.
12| If you are unable to process the specimen immediately upon receipt (optimal), place it in cryopreservation medium (Re-
agent Setup). Freeze it on dry ice and store it at −80 °C for up to 1 week, or freeze in liquid nitrogen for long-term storage.
 pause poInt Cryopreserved tissue specimens may be kept indefinitely.
13| To isolate primary cells from human prostate, breast, lung, salivary gland, cervix and liver tissue, follow option A; 
to isolate primary cells from human colon and pancreas tissue, follow option B; and to isolate primary cells from  
cryopreserved human tissue, follow option C.
(a) Isolation of primary cells from human prostate, breast, lung, salivary gland, cervix and liver tissue
● tIMInG 2–4 h
(i)  Dilute one part of 10× collagenase/hyaluronidase solution with nine parts of F medium and place the solution
into a 15-ml tube.
(ii) Mix 3 ml of F medium/collagenase/hyaluronidase with 1 ml of dispase.
(iii)  Quickly rinse resected tissue sample(s) with 95–100% ethanol (up to 3 s) and then with cold (4 °C) PBS.
? troublesHootInG
(iv) Mince the tissue with a scalpel into small (<10 mm) pieces.
(v)  Transfer the tissue fragments to the 15-ml tube containing 4 ml of F medium/collagenase/hyaluronidase/dispase
and incubate for 1–3 h at 37 °C on a rocking platform.
(vi) After dissociation, centrifuge the cells at 500g for 5 min at 4 °C and discard the supernatant.
(vii)  Resuspend the cell pellet in 10 ml of complete DMEM. Filter the cell suspension through a 100-µm cell strainer
into a new 50-ml centrifuge tube. Centrifuge at 300g for 5 min at 4 °C and discard the supernatant.
(b) Isolation of primary cells from human colon and pancreas tissue ● tIMInG 2–4 h
(i)  Rinse resected tissue sample(s) with 95–100% ethanol (up to 3 s) and then with cold (4 °C) PBS (as in Step 13A(iii),
and transfer the samples to a sterile Petri dish.
(ii) Mince the tissue with a scalpel into small (<10 mm) pieces.
(iii)  Transfer the tissue fragments to the tube containing collagenase IV (4 ml) and incubate for 15 min at 37 °C,
on a rocking platform.
 crItIcal step Do not extend collagenase IV treatment longer than 20 min.
(iv) Add 7 ml of DMEM to the tube and mix gently.
(v)  Filter the cell suspension through a 100-µm cell strainer into a new 50-ml centrifuge tube. Centrifuge at 300g for
5 min at 4 °C and discard the supernatant.
(vi)  Resuspend the cell pellet in complete F medium (or CM, for normal colon tissue samples, as shown in table 1) and
plate in a collagen-I-coated T25 flask (Reagent Setup). Total media volume is 5 ml. Change the medium every 7 d.
! cautIon The cell lines generated should be regularly checked to ensure that they are authentic and are not infected
with mycoplasma.
 crItIcal step Maintain cell cultures in a variable oxygen control incubator with a low oxygen level (2% O2). 
? troublesHootInG
(c) Isolation of primary cells from cryopreserved human tissue ● tIMInG 2–4 h
(i) Thaw the container of tissue (in cryopreservation medium) in a 37 °C water bath.
(ii) Remove tissue from the container using sterile forceps.
(iii) Place the tissue on a sterile Petri dish containing sufficient sterile PBS to rinse.
(iv)  Move the piece of tissue onto another sterile Petri dish and proceed as in Step 13A(iv–vii) (for prostate,
breast, lung, salivary gland, cervix and liver tissue) or Step 13B(ii–vi) (for colon and pancreas tissue).
Feeder cell irradiation and coculture ● tIMInG 1 h 
14| For the irradiation procedure, start with a T175 flask of J2 cells (2 × 104 cells/cm2) in DMEM.
 crItIcal step Never grow J2 cells above 90% confluence. Overgrowth changes their sensitivity to irradiation.
15| Detach the cells as described in Steps 3–5 and resuspend the cell pellet in 10 ml of DMEM.
16| Irradiate the cell suspension with an appropriate Cesium Irradiator at 30 Gy (=3,000 rad).
 crItIcal step Using a parallel culture, ensure that there is no proliferation of J2 cells after irradiation. (This is necessary 
only until it is clear that the routine irradiation is sufficient to stop proliferation.)
? troublesHootInG
17| Immediately after irradiation, plate the J2 cells in a T25 flask (1 × 104 cells/cm2) together with processed tissue or  
desired epithelial cells in complete F medium. Alternatively, prepare CM and plate epithelial cells using CM following the 
steps in box 1. Store excess irradiated J2 feeder cells at 4 °C in DMEM in a sterile 15-ml tube. Use them within 4 d or  
freeze the cells in cryopreservation medium at –80 °C for up to 1 week or place in liquid nitrogen for long-term storage 
as described in Step 12.
! cautIon Swiss-3T3-J2 mouse fibroblasts should be regularly checked to ensure that they are not infected with mycoplasma.
? troublesHootInG
18| Maintain coculture/s at 37 °C, 95% humidity and 5% CO2 until confluent.
! cautIon The cell lines generated should be regularly checked to ensure that they are authentic and are not infected
with mycoplasma.
Differential trypsin treatment for passage of cocultured cells ● tIMInG 0.5 h
19| Rinse coculture with PBS and incubate with 1 ml of 0.05% trypsin/EDTA solution (for a T25 flask) at room 
temperature for 20 s.
20| Monitor closely using a phase-contrast microscope. When the feeder cells become round and begin to detach from the sub-
strate, tap the flask gently and remove the detached cells by aspiration. Colonies of epithelial cells should remain tightly adherent.
 crItIcal step Do not extend trypsin/EDTA incubation time longer than 1 min.
? troublesHootInG
21| Rinse the epithelial cells with PBS and re-treat them with 1 ml of 0.05% trypsin/EDTA at 37 °C for 5 min.
22| Stop the trypsin/EDTA incubation by adding four volumes of complete DMEM to the cells and transfer the mixture 
to a 15-ml centrifuge tube.
23| Centrifuge the cells at 300g for 5 min at 4 °C.
24| After centrifugation, resuspend the cell pellet in complete F medium.
25| During passaging, surplus epithelial cells can be cryopreserved (Step 12).
? troublesHootInG
26| To assess the cells, follow option A for time-lapse microscopy and cell motility testing, or option B to perform a cell 
invasion assay.
 pause poInt Cryopreserved cells can be stored indefinitely.
(a) time-lapse microscopy and cell motility testing ● tIMInG 1–5 d
(i)  Plate 103 epithelial cells in a six-well plate, together with irradiated feeder cells (104 cells/cm2) or CM. Place the
coculture in a tissue culture incubator overnight.
Box 1 | Procedure for preparation of CM and plating of cells using CM 
● tIMInG 3 d and 1 h, respectively
1. Plate 7 × 106 irradiated J2 cells in a T175 flask in 30 ml of F medium.
 crItIcal step If complete serum-free CM is necessary, replace FBS with 20% KSR before conditioning by irradiated J2 cells.
2. Incubate the cells for 72 h at 37 °C.
 crItIcal step To obtain the optimal concentration of factors released by the irradiated J2 cells, allow the F medium to be
conditioned for 72 h.
?  troublesHootInG
3. Transfer the medium to 50-ml conical tubes and centrifuge at 300g for 5 min at 4 °C.
4. Collect the supernatant and filter using a 0.22-µm vacuum filtration system.
5. Aliquot into 15-ml conical tubes. For immediate use, mix three parts of the filtered supernatant with one part of fresh F medium
and supplement with 10 µM Y-27632. The resulting complete CM can be stored at 4 °C up to 1 week.
 pause poInt For longer storage, freeze complete CM on dry ice and store at −80 °C for up to 6 months.
6. For epithelial cells that require culturing in CM (table 1), or for all epithelial cells after three passages in standard CR coculture,
plate in complete CM (if desired). (Use all cells when plating from dissociated tissue; split 1:4–1:20 for existing cultures, depending
on the growth rate.)
7. Change the medium every 2–3 d; passage when confluent.
(ii)  Check cell confluence the next morning.
? troublesHootInG
(iii) Aspirate the medium from the cells and add 7 ml of fresh complete F medium to each well.
(iv)  Place the six-well plate in an incubator (37 °C, 5% CO2) equipped with a microscope, camera and time-lapse
recording system.
 crItIcal step Prepare the incubator by setting an appropriate temperature, CO2 concentration and humidity level.
Prewarm the plate to 37 °C before placing it in the incubator in order to eliminate water condensation, which
degrades visibility.
? troublesHootInG
(v)  Check the visibility and condition of the cells and choose fixed points as areas the pictures will be taken from
(as required by the software).
(vi) Set up the software to take a picture of each area every 15 min.
(vii)  Record cell motility (1–4 d).
 crItIcal step Each day check the temperature, CO2 concentration and humidity level in the incubator and
adjust if necessary.
? troublesHootInG
(viii) Stop recording. Make a video document using the Volocity 6.2.1 software (or equivalent).
(b) cell invasion assay ● tIMInG 2.5 d
(i) Place the xCELLigence RTCA DP instrument in a standard tissue culture incubator (37 °C, 5% CO2).
(ii) Coat 16-well E-plates with 100 µl per well of 0.1% gelatin for 1 h at 37 °C and rinse three times with PBS.
(iii) Add 200 µl of EGM-2 per well.
(iv) Add of 3.5 × 104 HUVECs per well and incubate them for 21 h to allow a monolayer to form.
(v)  Aspirate the EGM-2 medium and replace it with 200 µl per well of complete F medium containing 104 normal or
tumor CR cells originating from the head and neck region. Incubate the cells for 10 h.
(vi) Return the plate to the xCELLingence RTCA instrument and set the background to zero. Record data for 11 h.
(vii) Analyze the data using Acea RT-CA software, which is included with the xCELLigence RTCA DP system.
? troublesHootInG
Troubleshooting advice can be found in table 3.
table 3 | Troubleshooting table.
step problem possible reason possible solution
1 No growth or slow growth of epithelial 
cells in coculture
Use of a nonrecommended 
feeder cell line
Use only the J2 strain of mouse Swiss-3T3 
fibroblasts
13A(iii) No live cells after tissue processing Extended ethanol rinse time Rinse no longer than 3 s
13B(vi) No growth of colon or pancreas 
cell lines
Incubation in an incubator with 
an atmospheric gas mixture
Incubate in low oxygen (2% O2)
16 Observed J2 cell proliferation after 
irradiation
Irradiation dose is too low Increase irradiation dose (up to 60 Gy)
17 Low cell viability after freeze–thaw 
procedure
Storage of cells at −80 °C Store cells in a liquid nitrogen freezer
20 Epithelial cells detach together with 
J2 feeder cells during first step of  
differential trypsin treatment
Trypsin treatment was too long Do not extend trypsin treatment beyond 1 min
25 Low cell viability after freeze–thaw 
procedure
Storage of cells at −80 °C Store cells in a liquid nitrogen freezer
26A(ii) No colonies visible when 
recording starts
Cell confluence is too low Increase the number of cells added to the wells
26A(iv) No cells visible Condensation on the plate 
surfaces
Let the plate adapt to incubator conditions 
for at least 30 min
(continued)
● tIMInG
Steps 1–5, feeder cell culture: 1 h
Steps 6–12, fresh tissue handling, transportation and shipping: 0.5 h
Step 13A, isolation of primary cells from human prostate, breast, lung, salivary gland, cervix and liver tissue: 2–4 h
Step 13B, isolation of primary cells from human colon and pancreas tissue: 2–4 h
Step 13C, isolation of primary cells from cryopreserved human tissue: 2–4 h
Steps 14–18, feeder cell irradiation and coculture: 1 h
Steps 19–25, differential trypsin treatment for passage of cocultured cells: 0.5 h
Step 26A, time-lapse microscopy and cell motility testing: 1–5 d
Step 26B, cell invasion assay: 2.5 d
box 1, conditioned medium preparation and plating of cells using conditioned medium: 3 d and 1 h, respectively
antIcIpateD results
This procedure describes how to generate approximately a million cells from a variety of fresh or cryopreserved human  
tissue biopsies in as little as 7 d. ‘Fast-growing’ tissues (e.g., prostate, lung, cervix, skin and salivary gland tissues) can 
yield up to 2 million cells after 6–7 d. Tissues with an intermediate growth rate (breast and kidney tissues) yield 1–2 million 
cells after ~2 weeks. ‘Slow-growing’ tissues (colon, pancreas, ovary and thyroid tissues) yield ~10,000 cells after 4 weeks.  
We have not observed any consistent differences between the growth rates of normal and tumor cells from the same tissue. 
The viability of cells at the initial plating from dissociated tissue is 80–90% (using trypan blue staining).
It is important to note that normal and tumor CR cell cultures can be generated from the same patient, including for rare 
tumors such as adenocystic carcinoma of the salivary gland and neuroendocrine cervical cancer, for which few or no cell lines 
exist. CR cultures are suitable for early-stage, late-stage, low-grade, high-grade and metastatic tumors, which should aid  
tremendously in investigating progression from pre-neoplastic to neoplastic to metastatic states. Furthermore, CR cultures 
make an in-depth analysis of tumor heterogeneity possible, as they preserve the cellular diversity of tumors. Finally,  
CR cell cultures can be generated from xenograft and organoid tissue, suggesting that these three platforms can work in 
synergy to advance research into both normal and cancer cell biology using primary human-tissue-derived cells51.
As CR cells maintain developmental potential and differentiate into 3D cultures representative of their tissue of origin 
in vitro or in xenografts upon removal of CR conditions, developmental abnormalities associated with specific tumor cells can 
be analyzed by immunohistochemical analysis of frozen or paraffin-embedded sections.
table 3 | Troubleshooting table (continued).
step problem possible reason possible solution
26A(vii) No motility; wrong cell morphology Temperature, CO2 concentration 
and/or humidity not correct
Make sure that temperature, CO2 level and 
humidity level are within the range for cell 
growth
box 1 Low quality of conditioned  
medium-does not support cell growth
Suboptimal concentration of 
growth factors
Use the correct number of cells. Condition the 
medium for no less than 72 h
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Corrigendum: Conditional reprogramming and  
long-term expansion of normal and tumor cells 
from human biospecimens
Xuefeng Liu, Ewa Krawczyk, Frank A Suprynowicz, Nancy Palechor-Ceron, Hang Yuan, Aleksandra Dakic,  
Vera Simic, Yun-Ling Zheng, Praathibha Sripadhan, Chen Chen, Jie Lu, Tung-Wei Hou, Sujata Choudhury, 
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Scott H Randell, Christopher Albanese, Seema Agarwal & Richard Schlegel
Nat. Protoc. 12, 439–451 (2017); published online 26 January 2017; corrected after print 6 April 2017; doi:10.1038/nprot.2016.174.
In the version of this article initially published, a middle initial was missing for one of the authors (Dean G. Tang). The error 
has been corrected in the HTML and PDF versions of the article.
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